[go: up one dir, main page]

HRP970224A2 - TREATMENT OF ASTHMA WITH TNFR-Ig - Google Patents

TREATMENT OF ASTHMA WITH TNFR-Ig

Info

Publication number
HRP970224A2
HRP970224A2 HR60/016,842A HRP970224A HRP970224A2 HR P970224 A2 HRP970224 A2 HR P970224A2 HR P970224 A HRP970224 A HR P970224A HR P970224 A2 HRP970224 A2 HR P970224A2
Authority
HR
Croatia
Prior art keywords
tnfr
asthma
treatment
Prior art date
Application number
HR60/016,842A
Inventor
Louis Martin Renzetti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP970224A2 publication Critical patent/HRP970224A2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR60/016,842A 1996-05-08 1997-05-02 TREATMENT OF ASTHMA WITH TNFR-Ig HRP970224A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
HRP970224A2 true HRP970224A2 (en) 1998-04-30

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
HR60/016,842A HRP970224A2 (en) 1996-05-08 1997-05-02 TREATMENT OF ASTHMA WITH TNFR-Ig

Country Status (15)

Country Link
EP (1) EP0910413A2 (en)
JP (1) JP2000510113A (en)
KR (1) KR20000010825A (en)
CN (1) CN1233189A (en)
AR (1) AR007020A1 (en)
AU (1) AU725408B2 (en)
BR (1) BR9708928A (en)
CA (1) CA2253557A1 (en)
CO (1) CO4820397A1 (en)
HR (1) HRP970224A2 (en)
MA (1) MA24169A1 (en)
PE (1) PE70698A1 (en)
TR (1) TR199802238T2 (en)
WO (1) WO1997041895A2 (en)
ZA (1) ZA973843B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136988A0 (en) * 1997-12-29 2001-06-14 Regeneron Pharma Novel nucleic acid and polypeptide
TR200504220T2 (en) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CN100563712C (en) * 2003-02-28 2009-12-02 阿雷斯贸易股份有限公司 Liquid formulations of tumor necrosis factor binding protein
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
CA2666934A1 (en) 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399023I2 (en) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
EP0772449A1 (en) * 1994-07-22 1997-05-14 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
AU2776497A (en) 1997-11-26
WO1997041895A3 (en) 1998-03-12
TR199802238T2 (en) 1999-02-22
AU725408B2 (en) 2000-10-12
BR9708928A (en) 2000-05-09
CO4820397A1 (en) 1999-07-28
WO1997041895A2 (en) 1997-11-13
JP2000510113A (en) 2000-08-08
KR20000010825A (en) 2000-02-25
EP0910413A2 (en) 1999-04-28
MA24169A1 (en) 1997-12-31
AR007020A1 (en) 1999-10-13
CA2253557A1 (en) 1997-11-13
CN1233189A (en) 1999-10-27
ZA973843B (en) 1997-11-10
PE70698A1 (en) 1998-11-18

Similar Documents

Publication Publication Date Title
ZA966240B (en) Methods for treatment of allergic asthma.
EP1006960A4 (en) Comfortable orthopaedic support and the method of making the same
IL113850A0 (en) Process and intermediates for the preparation of 3-aryluracils
GB9617780D0 (en) Method of treatment
EP0914115A4 (en) Methods of providing neuroprotection
ZA979731B (en) Treatment of asthma.
AU2058697A (en) Treatment of sleep disorders
IL109656A0 (en) Process for the manufacture of androstane-17-carbothioates and androstane-17-carbothioates prepared thereby
AU3552697A (en) Novel treatment of leptine resistance
HU9700071D0 (en) Use of muramilpeptides
HRP970224A2 (en) TREATMENT OF ASTHMA WITH TNFR-Ig
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate
HU9702479D0 (en) New polymorphe modification of doxazosin-mesylate
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
GB9415901D0 (en) Novel compounds and treatment
EP0799225A4 (en) Compounds and methods
GB9415900D0 (en) Novel compounds and treatment
EP0761932A4 (en) Sliding part and method of manufacturing the same
AU1587295A (en) The treatment of gaseous substances
AU3430795A (en) Treatment of fabrics
KR0107727Y1 (en) Crutch
AUPO019296A0 (en) Treatment of asthma
GB2286983B (en) Method of securing knobs
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBI Application refused